Evidence map›Paper›PMID 38703333›Full record

Trial reportJournal of gastrointestinal cancer2024

Prognostic Impact of Post-operative Infectious Complications in Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy: Post Hoc Analysis of a Randomized Controlled Trial, JCOG0501.

Masato Hayashi, Takaki Yoshikawa, Junki Mizusawa, Shinji Hato, Yoshiaki Iwasaki, Mitsuru Sasako, Yasuyuki Kawachi, Hiroyasu Iishi, Yasuhiro Choda, Narikazu Boku and 1 more

Abstract readRandomized Controlled TrialClinical Trial, Phase III
PubMed Publisher
In one paragraph

Trial report in Journal of gastrointestinal cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Safety, survival outcomes, and prognostic factors in conversion surgery for advanced gastric cancer: a sub-analysis of Japanese patients in the CONVO-GC-1 study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Masato HayashiDepartment of Surgery, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan.
Takaki YoshikawaDepartment of Gastric Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. tayoshik@ncc.go.jp.
Junki MizusawaJCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Shinji HatoDepartment of Gastroenterological Surgery, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
Yoshiaki IwasakiDepartment of Surgery, IMS Tokyo Katsushika General Hospital, Tokyo, Japan.
Mitsuru SasakoDepartment of Surgery, Yodogawa Christian Hospital, Osaka, Japan.
Yasuyuki KawachiDepartment of Surgery, Nagaoka Chuo General Hospital, Niigata, Japan.
Hiroyasu IishiDepartment of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.
Yasuhiro ChodaDepartment of Surgery, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
Narikazu BokuDepartment of Medical Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Masanori TerashimaDivision of Gastric Surgery, Shizuoka Cancer Center, Shizuoka, Japan.

Funding

Grant-in-Aid for Clinical Cancer Research H19-15National Cancer Center Research and Development Funds 23-A-19
6 · The paper itself

Abstract

purposePost-operative infectious complication (IC) is a well-known negative prognostic factor, while showing neoadjuvant chemotherapy (NAC) may cancel out the negative influence of IC. This analysis compared the clinical impacts of IC according to the presence or absence of NAC in gastric cancer patients enrolled in the phase III clinical trial (JCOG0501) which compared upfront surgery (arm A) and NAC followed by surgery (arm B) in type 4 and large type 3 gastric cancer.

methodsThe subjects were 224 patients who underwent R0 resection out of 316 patients enrolled in JCOG0501. The prognoses of the patients with or without ICs in each arm were investigated by univariable and multivariable Cox regression analyses.

resultsThere were 21 (20.0%) IC occurrences in arm A and 15 (12.6%) in arm B. In arm A, the overall survival (OS) of patients with ICs was slightly worse than those without IC (3-year OS, 57.1% in patients with ICs, 79.8% in those without ICs; adjusted hazard ratio (95% confidence interval), 1.292 (0.655-2.546)). In arm B, patients with ICs showed a trend of better survival than those without ICs (3-year OS, 80.0% in patients with IC, 74.0% in those without IC; adjusted hazard ratio, 0.573 (0.226-1.456)).

conclusionThis study could not indicate the negative prognostic influence of ICs in gastric cancer patients receiving NAC, which might be canceled by NAC. To build exact evidence, further investigation with prospective and large numbers of data might be expected.

Indexed as

Neoadjuvant TherapyStomach NeoplasmsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantFemaleGastrectomyHumansMaleMiddle AgedPostoperative ComplicationsPrognosisGastric cancerNeoadjuvant chemotherapyPostoperative complication

Identifiers

PMID38703333

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.